Los estudios de fase III EAGLE-2 y EAGLE-3 con gepotidacina se han detenido
Los estudios de fase III EAGLE-2 y EAGLE-3 con gepotidacina se han detenido por eficacia tras un análisis intermedio llevado
Leer másLos estudios de fase III EAGLE-2 y EAGLE-3 con gepotidacina se han detenido por eficacia tras un análisis intermedio llevado
Leer másLa jornada “Vivir con enfermedades eosinofílicas” ha permitido incrementar la visibilidad de las enfermedades eosinofílicas mediante experiencias de pacientes y
Leer másConéctaLES es un programa de apoyo a las pacientes que viven con Lupus Eritematoso Sistémico (LES) GSK lanza ConéctaLES, un
Leer másCookie | Duración | Descripción |
---|---|---|
cookielawinfo-checkbox-analytics | 11 months | This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics". |
cookielawinfo-checkbox-functional | 11 months | The cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional". |
cookielawinfo-checkbox-necessary | 11 months | This cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary". |
cookielawinfo-checkbox-others | 11 months | This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other. |
cookielawinfo-checkbox-performance | 11 months | This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance". |
viewed_cookie_policy | 11 months | The cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data. |